Abera Bioscience (ABERA) Q3 2025 earnings summary

Executive summary

• Achieved significant milestones in vaccine development, with preclinical and regulatory progress for pneumococcal and influenza candidates.

• Secured financing through a fully subscribed directed share issue, raising up to 21.5 MSEK, and additional grants from CEPI and BactiVac.

• Preparing for clinical phase 1 trials for the lead pneumococcal vaccine candidate, targeting study start in 2026.

• Strengthened position in mucosal immunization and pandemic preparedness, with ongoing collaborations and proof-of-concept data.

Financial highlights

• Q3 2025 operating income: 4,919 KSEK (up from 3,348 KSEK year-over-year), mainly from grants and currency gains.

• Net loss after financial items for Q3: -835 KSEK (vs. -278 KSEK year-over-year); nine-month net loss: -1,656 KSEK (vs. -1,302 KSEK year-over-year).

• Cash and bank at period end: 23,176 KSEK (vs. 3,105 KSEK year-over-year).

• Equity at period end: 28,083 KSEK (vs. 8,524 KSEK year-over-year).

• Cash flow from operations in Q3: -4,427 KSEK; total period cash flow: 15,229 KSEK.

Outlook and guidance

• Financing secured for GMP production and phase 1 clinical studies of the pneumococcal vaccine.

• Additional grant funding expected from CEPI and UK Vaccine Network through early 2026, supporting ongoing R&D.

• Focus on advancing both pneumococcal and influenza vaccine programs to clinical phase in the coming year.